Lipitor is named as an intervention in 7 current clinical trials in our Norway, Netherlands, Canada, Taiwan, Australia and Israel registers. 4 are recruiting patients now. The most common phase is Phase 2. The sponsor with the most trials is St. Olavs Hospital (2). The most-studied condition is Atherosclerosis.
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Atherosclerosis | 1 |
| Melanoma | 1 |
| Immune-related Adverse Event | 1 |
| Chronic Migraine | 1 |
| Episodic Migraine | 1 |
| Pancreatic Ductal Adenocarcinoma | 1 |
| Pancreatic Cancer | 1 |
| Pancreas Cancer | 1 |
| Metastatic Cancer | 1 |
| Thyroid Eye Disease, TED | 1 |
| Graves Ophthalmopathy | 1 |
| Independent Living | 1 |
| Disability Free Survival | 1 |
| Elderly | 1 |
| Healthy | 1 |
| Cardiac Toxicity | 1 |
| Early-stage Breast Cancer | 1 |
| Lead sponsor | Trials |
|---|---|
| St. Olavs Hospital | 2 |
| Erasmus Medical Center | 1 |
| CHU de Quebec-Universite Laval | 1 |
| Taipei Veterans General Hospital, Taiwan | 1 |
| Monash University | 1 |
| Rutgers, The State University of New Jersey | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in Norway | 2 | 2 |
| Clinical trials in Netherlands | 1 | 0 |
| Clinical trials in Canada | 1 | 0 |
| Clinical trials in Taiwan | 1 | 1 |
| Clinical trials in Australia | 1 | 0 |
| Clinical trials in Israel | 1 | 1 |
A trial with sites in more than one country appears in each of those registers.
7 current trials in our Norway, Netherlands, Canada, Taiwan, Australia and Israel registers name Lipitor as a drug or biological intervention, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.
Yes. 4 of the 7 trials are recruiting: 2 with sites in Norway, 1 with sites in Taiwan and 1 with sites in Israel. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
St. Olavs Hospital (2), Erasmus Medical Center (1), CHU de Quebec-Universite Laval (1) and Taipei Veterans General Hospital, Taiwan (1), among 6 lead sponsors in total. The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Lipitor works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Lipitor works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Lipitor (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 26 Sep 2026.